Article ; Online: Potential renoprotective effect of SGLT2 inhibitors against contrast-induced AKI in diabetic STEMI patients undergoing primary PCI.
2024 Volume 82, Issue 1, Page(s) 29–36
Abstract: Background: It has been demonstrated that there is a significant reduction in the incidence of cardiovascular events, mortality rates, and worsening kidney disease in patients using sodium-glucose cotransporter 2 inhibitors (SGLT2i). However, there is ... ...
| Abstract | Background: It has been demonstrated that there is a significant reduction in the incidence of cardiovascular events, mortality rates, and worsening kidney disease in patients using sodium-glucose cotransporter 2 inhibitors (SGLT2i). However, there is limited information about the effect of SGLT2i on the incidence of contrast-induced acute kidney injury (CI-AKI) in patients undergoing primary percutaneous intervention (pPCI). Aims: Our research was focused on examining how SGLT2i exposure impacts CI-AKI occurrence in patients with ST-segment elevation myocardial infarction (STEMI) and undergoing pPCI. Results: This retrospective, single-center, case-control study included diabetic patients diagnosed with STEMI who underwent pPCI in a tertiary healthcare center between 2021 and 2022. The study population included SGLT2i users (n = 130) and non-SGLT2i users (n = 165). Inverse probability propensity score weighting and doubly robust estimation were performed to decrease bias and to balance covariate distribution for estimating average treatment for those treated. In a doubly robust inverse probability weighted regression model, in which covariates were balanced, CI-AKI risk was also found to be lower in the SGLT2i-user group (OR: 0.86 [0.76-0.98]; 95% CI; P = 0.028). In addition, ejection fraction, admission creatinine, albumin, and volume of contrast media were found to be independent predictors of CI-AKI in patients presenting with STEMI and undergoing pPCI. Conclusion: Our study provides evidence supporting the potential protective effect of SGLT2i against CI-AKI in diabetic patients presenting with STEMI and undergoing pPCI. |
|---|---|
| MeSH term(s) | Humans ; ST Elevation Myocardial Infarction/drug therapy ; ST Elevation Myocardial Infarction/surgery ; ST Elevation Myocardial Infarction/complications ; Sodium-Glucose Transporter 2 Inhibitors/adverse effects ; Retrospective Studies ; Case-Control Studies ; Percutaneous Coronary Intervention/adverse effects ; Contrast Media/adverse effects ; Acute Kidney Injury/chemically induced ; Acute Kidney Injury/prevention & control ; Diabetes Mellitus ; Risk Factors |
| Chemical Substances | Sodium-Glucose Transporter 2 Inhibitors ; Contrast Media |
| Language | English |
| Publishing date | 2024-01-17 |
| Publishing country | Poland |
| Document type | Journal Article |
| ZDB-ID | 411492-9 |
| ISSN | 1897-4279 ; 0022-9032 |
| ISSN (online) | 1897-4279 |
| ISSN | 0022-9032 |
| DOI | 10.33963/v.kp.98260 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.B 598: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
|||
| Zs.MO 474: Show issues |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.